Table 2.
Anti-HIV-1 efficacy of 7u–7am.
| Compd. | R | EC50a (μmol/L) | CC50b (μmol/L) | SIc |
|---|---|---|---|---|
| 7u |  |
0.89 ± 0.23 | 276.6 ± 10.08 | 309.52 |
| 7v |  |
4.48 ± 1.24 | 278.33 ± 18.59 | 62.10 |
| 7w |  |
0.022 ± 0.01 | 273.95 ± 10.56 | 12,497.73 |
| 7x |  |
1.23 ± 0.28 | >299 | >244 |
| 7y |  |
8.07 ± 1.41 | 220.30 ± 35.48 | 27.30 |
| 7z |  |
>233 | 233.26 ± 32.085 | <1 |
| 7aa |  |
>220.31 | 220.31 ± 44.35 | <1 |
| 7ab |  |
>232.67 | 232.67 ± 26.13 | <1 |
| 7ac |  |
>151.44 | 151.44 ± 27.93 | <1 |
| 7ad |  |
>244.18 | 244.18 ± 13.78 | <1 |
| 7ae |  |
11.73 ± 9.10 | 92.86 ± 43.99 | 7.92 |
| 7af |  |
33.26 ± 9.61 | 81.53 ± 11.72 | 2.45 |
| 7ag |  |
>250 | >250 | >1 |
| 7ah |  |
251.59 ± 5.75 | >299 | >1 |
| 7ai |  |
11.15 ± 2.83 | >299 | >27 |
| 7aj |  |
20.53 ± 8.02 | >299 | >15 |
| 7ak |  |
>192.06 | 192.06 ± 42.91 | <1 |
| 7al |  |
46.69 ± 12.48 | 171.6 ± 44.92 | 3.68 |
| 7am |  |
>163.98 | 163.98 ± 25.49 | <1 |
| ZLM-66 | – | 0.013 ± 0.0034 | 26.45 ± 2.42 | 2019.80 |
| DOR | – | 0.013 ± 0.004 | 293.24 ± 0.17 | 22,556.92 |
| ETR | – | 0.0029 ± 0.002 | >4.60 | >1600 |
a
EC50: concentration of compound required to achieve 50% protection of MT-4 cell cultures against HIV-1-induced cytotoxicity, as determined by the MTT method, and values are the mean ± SD of at least two parallel tests.
b
CC50: concentration required to reduce the viability of mock-infected cell cultures by 50%, as determined by the MTT method, and values were averaged from at least four independent experiments.
c
SI: selectivity index, the ratio of CC50/EC50.